Genentech/Roche Deal History & Licensing Activity
Genentech/Roche is a life sciences. Over the past three years, Genentech/Roche has been involved in 19 licensing and acquisition transactions, with a primary focus on Small Molecules (9 deals). The company currently has 19 active clinical trials, primarily in Oncology.
Deals (12mo)
14
Active Trials
19
Top Modality
Small Molecules
Focus Area
Oncology
Genentech/Roche Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Genentech/Roche in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Undisclosed | Genentech | ADC | Phase 1 | collaboration | Aug 28, 2026 |
| Undisclosed | Genentech | ADC | Preclinical | collaboration | Aug 28, 2026 |
| HM17321 | Genentech | Peptides | Phase 1 | license | Aug 24, 2026 |
| ExPERT GTx | Genentech | Cell Therapy | Unknown | license | Jul 21, 2026 |
| XmAb24306 (IL-15 cytokine therapeutic) | Xencor | Antibodies | Unknown | co development | Jul 10, 2026 |
| Undisclosed | Genentech | Small Molecules | Preclinical | collaboration | Jul 6, 2026 |
| Undisclosed | Genentech | Oligonucleotides | Preclinical | license | Feb 2, 2026 |
| Undisclosed | Genentech | Small Molecules | Preclinical | license | Jan 6, 2026 |
| Undisclosed | Genentech | Small Molecules | Unknown | license | Jan 6, 2026 |
| Undisclosed | Genentech | Small Molecules | Phase 1 | license | Dec 30, 2025 |
Showing 10 of 14 recent transactions. Upgrade to Pro for full deal history with financials.
Genentech/Roche Pipeline Focus
Therapeutic areas and modalities where Genentech/Roche is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Genentech/Roche Clinical Pipeline
Genentech/Roche has 19 active clinical trials across 6 development phases.
1
Phase 4
1
Not Applicable
2
Unknown
7
Phase 1
3
Phase 2
5
Phase 3
See How Your Asset Matches Genentech/Roche's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Genentech/Roche Licensing & Deal Activity
Genentech/Roche is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 19 deals over the past three years, Genentech/Roche ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Genentech/Roche include Oncology (13 deals and trials), Hematological Malignancies (8 deals and trials), Metabolic (6 deals and trials), and Other (6 deals and trials). In terms of modality, Genentech/Roche has shown particular interest in small molecules, other, adc.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Genentech/Roche and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Genentech/Roche's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.